Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABATE study of ACI-24.060 in prodromal Alzheimer's disease and Down syndrome adults
2022-500069-29-00Phase 2Authorised
- Sponsor
- AC Immune SA
- Start
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing ACI-24.060 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Planned start Aug 2022; status: authorised.
02
Drugs
ACI-24
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2022-500069-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500069-29-00.